Barclays Lowers Aveanna Healthcare (NASDAQ:AVAH) Price Target to $9.50

Aveanna Healthcare (NASDAQ:AVAH) had its target price cut by analysts at Barclays from $11.00 to $9.50 in a report released on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 43.72% from the company’s previous close.

A number of other brokerages have also recently issued reports on AVAH. Royal Bank Of Canada decreased their target price on Aveanna Healthcare from $11.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research report on Friday, March 20th. BMO Capital Markets decreased their price objective on Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Truist Financial lowered their target price on shares of Aveanna Healthcare from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Friday, March 20th. Finally, Zacks Research cut shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.38.

Aveanna Healthcare Stock Performance

Shares of AVAH stock opened at $6.61 on Wednesday. The stock’s 50-day moving average is $7.64 and its two-hundred day moving average is $8.45. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 6.48 and a beta of 2.07. Aveanna Healthcare has a 1 year low of $3.73 and a 1 year high of $10.32. The company has a debt-to-equity ratio of 6.62, a quick ratio of 1.32 and a current ratio of 1.32.

Insider Buying and Selling

In other news, CFO Matthew Buckhalter sold 13,512 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $97,421.52. Following the completion of the transaction, the chief financial officer directly owned 529,243 shares of the company’s stock, valued at approximately $3,815,842.03. This represents a 2.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25. Following the completion of the sale, the chief executive officer owned 2,650,892 shares in the company, valued at approximately $19,112,931.32. This trade represents a 6.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 998,595 shares of company stock worth $7,567,770 in the last three months. Company insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Aveanna Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Aveanna Healthcare by 252.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after purchasing an additional 2,400 shares during the period. Invesco Ltd. lifted its stake in shares of Aveanna Healthcare by 1,001.5% in the fourth quarter. Invesco Ltd. now owns 360,464 shares of the company’s stock valued at $2,945,000 after purchasing an additional 327,738 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Aveanna Healthcare by 12.7% in the fourth quarter. Mackenzie Financial Corp now owns 216,200 shares of the company’s stock valued at $1,810,000 after purchasing an additional 24,447 shares during the period. Zimmer Partners LP purchased a new stake in Aveanna Healthcare during the fourth quarter worth about $6,189,000. Finally, Voloridge Investment Management LLC purchased a new stake in Aveanna Healthcare during the fourth quarter worth about $1,915,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.